BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Department of Medicine, Karolinska Institute, Stockholm, Sweden.
JACC Heart Fail. 2022 Jun;10(6):380-392. doi: 10.1016/j.jchf.2022.04.006.
Hypertension is common in patients with heart failure (HF), but less is known about resistant hypertension.
This study sought to investigate apparent treatment-resistant hypertension (aTRH) in patients with HF in the SwedeHF (Swedish Heart Failure Registry), across the spectrum of HF phenotypes (heart failure with reduced ejection fraction [HFrEF], heart failure with mildly reduced ejection fraction [HFmrEF], and heart failure with preserved ejection fraction [HFpEF]).
aTRH was defined as systolic blood pressure ≥140 mm Hg (≥135 mm Hg in diabetes) despite treatment with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or sacubitril-valsartan, as well as a calcium-channel blocker and a diuretic; non-treatment-resistant hypertension (TRH) was defined as systolic blood pressure above these thresholds but not on the 3-drug combination; and normal blood pressure was defined as under these thresholds. In each left ventricular ejection fraction (LVEF) category, patient factors associated with aTRH and non-TRH and outcomes (HF hospitalization and cardiovascular death composite, its components, and all-cause death) according to hypertension category were examined.
Among 46,597 patients, aTRH was present in 2,693 (10%), 1,514 (14%), and 1,450 (17%) patients with HFrEF, HFmrEF, and HFpEF, respectively. Older age, obesity, diabetes, and kidney disease were associated with a greater likelihood of aTRH and non-TRH (vs normal blood pressure). Associations were generally similar irrespective of LVEF category. Compared with normal blood pressure, aTRH was associated with a lower adjusted risk of the composite outcome in HFrEF and HFmrEF (HR: 0.79 [95% CI: 0.74-0.85] and HR: 0.86 [95% CI: 0.77-0.96]) but not in HFpEF (HR: 0.93 [95% CI: 0.84-1.04]).
aTRH was most common in HFpEF and least common in HFrEF. Associated patient characteristics were similar irrespective of LVEF category. aTRH (vs normal blood pressure) was associated with a lower risk of first HF hospitalization or cardiovascular death in HFrEF and HFmrEF but not in HFpEF.
高血压在心力衰竭(HF)患者中很常见,但对耐药性高血压的了解较少。
本研究旨在调查心力衰竭患者中的显性治疗抵抗性高血压(aTRH),这些患者的心力衰竭表型(射血分数降低的心力衰竭 [HFrEF]、射血分数轻度降低的心力衰竭 [HFmrEF]和射血分数保留的心力衰竭 [HFpEF])各异。
aTRH 的定义为尽管接受了血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂或沙库巴曲缬沙坦治疗,以及钙通道阻滞剂和利尿剂治疗,但收缩压仍≥140mmHg(糖尿病患者≥135mmHg);非治疗抵抗性高血压(TRH)的定义为收缩压高于这些阈值但未接受三联药物治疗;血压正常定义为低于这些阈值。在每个左心室射血分数(LVEF)类别中,根据高血压类别,检查与 aTRH 和非 TRH 相关的患者因素以及与 HF 住院和心血管死亡复合终点相关的结局(其组成部分和全因死亡)。
在 46597 名患者中,HFrEF、HFmrEF 和 HFpEF 患者中分别有 2693 名(10%)、1514 名(14%)和 1450 名(17%)存在 aTRH。年龄较大、肥胖、糖尿病和肾脏疾病与 aTRH 和非 TRH(与血压正常相比)的可能性更大相关。这些关联在 LVEF 类别中通常相似。与血压正常相比,aTRH 与 HFrEF 和 HFmrEF 复合结局的调整后风险较低相关(HR:0.79 [95%CI:0.74-0.85]和 HR:0.86 [95%CI:0.77-0.96]),但在 HFpEF 中则不然(HR:0.93 [95%CI:0.84-1.04])。
aTRH 在 HFpEF 中最常见,在 HFrEF 中最不常见。与 LVEF 类别无关,相关的患者特征相似。与血压正常相比,aTRH 与 HFrEF 和 HFmrEF 中的首次 HF 住院或心血管死亡风险降低相关,但与 HFpEF 中无关。